Literature DB >> 842587

Serum progesterone and estradiol-17beta levels in premature and term labor.

L M Cousins, C J Hobel, R J Chang, D M Okada, J R Marshall.   

Abstract

A total of 30 to 50 per cent of premature labors occur without identifiable predisposing conditions. To evaluate the hormonal status of these pregnancies, serum progesterone (P) and estradiol (E2) were measured by radioimmunoassay singly in 60 premature labor patients and serially in 19 normal pregnancies. Premature labor patients as a group have significantly lower P and E2 levels than controls. Pregnancies complcated by idiopathic premature labor (IPL) (p less than 0.01), premature labor secondary to abruptio-marginal separation (A-MS) (p less than 0.05), and premature rupture of membranes (PROM) (p less than 0.05) have significantly lower P levels than controls. Patients with IPL and A-MS have significantly lower P levels (p less than 0.01) than PROM patients. No significant change in P or E2 occurs immediately prior to normal term labor. Conclusions are that (1) premature labor patients have significantly lower Pand E2 levels than controls, (2) the degree of P depression varies according to the type of premature labor and (3) IPL is characterized by premature labor with no identifiable predisposing factors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 842587     DOI: 10.1016/0002-9378(77)90359-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  Progesterone treatment to prevent preterm birth.

Authors:  Paul J Meis; Alicia Aleman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Experimental gestational pyelonephritis induces preterm births and low birth weights in C3H/HeJ mice.

Authors:  A K Kaul; S Khan; M G Martens; J T Crosson; V R Lupo; R Kaul
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Role of 17 α Hydroxy Progesterone Caproate (17OHPC) in the Prevention of Preterm Labor.

Authors:  Asma Nigar; S Hakim; Zehra Mohsin
Journal:  J Obstet Gynaecol India       Date:  2012-10-23

4.  Increased saliva oestriol to progesterone ratio before preterm delivery: a possible predictor for preterm labor?

Authors:  J Darne; H H McGarrigle; G C Lachelin
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

5.  Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.

Authors:  Mark A Klebanoff; Paul J Meis; Mitchell P Dombrowski; Yuan Zhao; Atef H Moawad; Allison Northen; Baha M Sibai; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Kenneth J Leveno; Menachem Miodovnik; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian M Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman
Journal:  Am J Obstet Gynecol       Date:  2008-05-23       Impact factor: 8.661

6.  Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Eszter Papp; Kayode Balogun; Nicole Banko; Hakimeh Mohammadi; Mona Loutfy; Mark H Yudin; Rajiv Shah; Jay MacGillivray; Kellie E Murphy; Sharon L Walmsley; Michael Silverman; Lena Serghides
Journal:  J Infect Dis       Date:  2016-01-05       Impact factor: 5.226

7.  Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen.

Authors:  Z Chen; I S Yuhanna; Z Galcheva-Gargova; R H Karas; M E Mendelsohn; P W Shaul
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

8.  Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial.

Authors:  Kaitlin Siou; Sharon L Walmsley; Kellie E Murphy; Janet Raboud; Mona Loutfy; Mark H Yudin; Michael Silverman; Noor N Ladhani; Lena Serghides
Journal:  Pilot Feasibility Stud       Date:  2016-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.